Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

Core Insights - Tango Therapeutics will present three posters at the SITC Annual Meeting 2025, showcasing the first clinical data on the novel CoREST inhibitor TNG260 in non-small cell lung cancer [1][2] Group 1: Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering and delivering precision cancer medicines [4] - The company utilizes the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related pathways [4] Group 2: Clinical Trials and Research - TNG260 is a first-in-class, highly selective CoREST complex inhibitor currently being evaluated in combination with pembrolizumab during the dose expansion phase of the Phase 1/2 trial [2] - The trial is enrolling patients with STK11-mutant/RAS wild type lung cancer, which represents approximately 10% of lung adenocarcinoma [2] - The accepted abstracts for poster presentations include studies on the safety, tolerability, pharmacokinetics, and efficacy of TNG260 in combination with pembrolizumab, as well as its ability to sensitize STK11-mutant tumors to anti-PD-1 therapy [3][4]